Vitamin D in children with cystic fibrosis
- Malcolm Brodlie1,2,
- William A Orchard2,
- Gordon A Reeks2,
- Stewart Pattman3,
- Helen McCabe2,
- Christopher J O'Brien2,
- Matthew F Thomas2,
- David Anthony Spencer2
- 1Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK
- 2Regional Paediatric Cystic Fibrosis Service, Department of Paediatric Respiratory Medicine, Great North Children's Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
- 3Chemical Pathology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
- Correspondence to Dr Malcolm Brodlie, c/o Paediatric Respiratory Secretaries, Old Children's Outpatients Department, Royal Victoria Infirmary, Newcastle upon Tyne NE1 4LP, UK;
- Received 21 November 2011
- Accepted 28 June 2012
- Published Online First 4 August 2012
Purpose The Cystic Fibrosis Trust in 2007 published a recommended target of 75-150 nmol/L for 25-hydroxyvitamin D (25-OHD). In 2008 we found that only 10% of pancreatic insufficient (PI) children met this target. An increase in supplementation was implemented and a repeat audit performed in 2010.
Methods PI children ≥1 year under sole-care in our regional centre were included. Vitamin D3 supplementation increased by >450% to either 3800 IU/day liquid or 800 IU daily plus 20,000 IU weekly tablets. In 2010 pancreatic sufficient (PS) children were also audited separately.
Results The median 25-OHD level increased from 51.5 nmol/L in 2008 (n=78, 10% >75 nmol/L) to 72 nmol/L in 2010 (n=72, 51% >75 nmol/L), p<0.0001. In PS children (n=15 in 2010) 87% had 25-OHD levels <75 nmol/L.
Conclusions A substantial increase in supplementation led to a significant increase in 25-OHD levels but around half still failed to reach the recommended target.